Literature DB >> 2162681

Antibiotic susceptibility and beta-lactamase production in clinical isolates of Enterobacter spp.

E Lindh1, K Dornbusch, K Jalakas, A Forsgren.   

Abstract

The in vitro susceptibility of 237 clinical isolates of Enterobacter spp. (E. aerogenes, E. agglomerans and E. cloacae; 41, 64 and 132 respectively) to 16 different antibiotics is described. Four quinolones (ciprofloxacin, lomefloxacin, norfloxacin and ofloxacin), two new cephalosporins (cefpirome and cefepime) and imipenem, all showed high activity against the three Enterobacter species tested (MIC50 less than or equal to 0.125 mg/l, MIC90 less than or equal to 0.5 mg/l). Also the aminoglycosides gentamicin and tobramycin were highly active antibiotics (MIC50 less than or equal to 0.5 mg/l, MIC90 less than or equal to 1.0 mg/l). The susceptibility of beta-lactam-antibiotics to beta-lactamase produced by Enterobacter spp. was evaluated, and imipenem and cefepime were found to be most stable. Different methods for detection of inducible beta-lactamases were used, the agar dilution method being more sensitive than the double-disc diffusion test. Elevated beta-lactamase production was detected, via induction, in 83% of E. aerogenes strains and 70% of E. cloacae strains, with cefamandole used as the substrate and cefoxitin as the inducer. Constitutive, high level enzyme production was detected in 7 and 13% respectively of the E. aerogenes and the E. cloacae strains. In all the strains of E. agglomerans, 10% of E. aerogenes and 13% of E. cloacae, no beta-lactamases could be detected with the methods studied.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162681

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

Review 1.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes.

Authors:  R N Charrel; J M Pagès; P De Micco; M Mallea
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 3.  Enterobacter spp.: pathogens poised to flourish at the turn of the century.

Authors:  W E Sanders; C C Sanders
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

4.  Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp.

Authors:  J D Pitout; E S Moland; C C Sanders; K S Thomson; S R Fitzsimmons
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Detection of resistance due to inducible beta-lactamase in Enterobacter aerogenes and Enterobacter cloacae.

Authors:  T W Huber; J S Thomas
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

Review 6.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.